ERK1/ATF-2 signaling axis contributes to interleukin-1β-induced MMP-3 expression in dermal fibroblasts


Autoři: Nanako Kitanaka aff001;  Rei Nakano aff001;  Manabu Sakai aff003;  Taku Kitanaka aff001;  Shinichi Namba aff001;  Tadayoshi Konno aff001;  Tomohiro Nakayama aff004;  Hiroshi Sugiya aff001
Působiště autorů: Laboratories of Veterinary Biochemistry, 3 Veterinary Internal Medicine, and 4Veterinary Radiotherapy, Nihon University College of Bioresource Sciences, Kameino, Fujisawa, Kanagawa, Japan aff001;  Laboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Suehiro-cho, Tsurumi, Yokohama, Kanagawa, Japan aff002;  Laboratories of Veterinary Internal Medicine, Nihon University College of Bioresource Sciences, Kameino, Fujisawa, Kanagawa, Japan aff003;  Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource Sciences, Kameino, Fujisawa, Kanagawa, Japan aff004
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0222869

Souhrn

Matrix metalloproteinases (MMPs) play a pivotal role in tissue remodeling by degrading the extracellular matrix (ECM) components. This mechanism is implicated in a variety of physiological and pathological cellular processes including wound healing. One of the key proteins involved in this process is the proinflammatory cytokine interleukin-1β (IL-1β, which induces the expression of MMP-3 mRNA and the secretion of MMP-3 protein by dermal fibroblasts. In this study, we first investigated the contribution of activating transcription factor 2 (ATF-2) to IL-1β-induced MMP-3 expression in dermal fibroblasts. Our results showed that in cells transfected with ATF-2 siRNA or treated with the ATF-2 inhibitor SBI-0087702, IL-1β-induced MMP-3 mRNA expression was reduced. We also demonstrated that IL-1β stimulates the phosphorylation of ATF-2. These observations suggest that ATF-2 plays an important role in IL-1β-induced MMP-3 expression. Next, we investigated the role of MAPK signaling in ATF-2 activation. In cells treated with the extracellular signal-regulated kinase (ERK) inhibitor FR180240, as well as in cells transfected with ERK1 and ERK2 siRNAs, IL-1β-induced MMP-3 mRNA expression was reduced. In addition, we showed that IL-1β induced the phosphorylation of ERK1/2. These observations suggest that ERK1 and ERK2 are involved in IL-1β-induced MMP-3 expression. However, ERK1 and ERK2 do seem to play different roles. While the ERK inhibitor FR180204 inhibited IL-1β-induced ATF-2 phosphorylation, only in cells transfected with ERK1 siRNA, but not ERK2 siRNA, IL-1β-induced ATF-2 phosphorylation was reduced. These findings suggest that the ERK1/ATF-2 signaling axis contributes to IL-1β-induced MMP-3 expression in dermal fibroblasts.

Klíčová slova:

Biology and life sciences – Cell biology – Cellular types – Animal cells – Connective tissue cells – Fibroblasts – Signal transduction – Cell signaling – Signaling cascades – MAPK signaling cascades – Cell motility – Cell migration – Anatomy – Biological tissue – Connective tissue – Genetics – Gene expression – Gene regulation – Small interfering RNAs – Biochemistry – Nucleic acids – RNA – Non-coding RNA – Proteins – Post-translational modification – Phosphorylation – DNA-binding proteins – Transcription factors – Regulatory proteins – Physiology – Physiological processes – Tissue repair – Wound healing – Developmental biology – Molecular biology – Molecular biology techniques – Transfection – Medicine and health sciences – Research and analysis methods


Zdroje

1. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997; 276: 75–81. doi: 10.1126/science.276.5309.75 9082989

2. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835–870. doi: 10.1152/physrev.2003.83.3.835 12843410

3. Angel P, Szabowski A. Function of AP-1 target genes in mesenchymal- epithelial cross-talk in skin. Biochem Pharmacol 2002; 64: 949–956. doi: 10.1016/s0006-2952(02)01158-9 12213591

4. Mauviel A. Transforming growth factor-beta signaling in skin: stromal to epithelial cross-talk. J Invest Dermatol 2009; 129: 7–9. doi: 10.1038/jid.2008.385 19078982

5. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE, et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 2000; 103: 745–755. doi: 10.1016/s0092-8674(00)00178-1 11114331

6. Florin L, Hummerich L, Dittrich BT, Kokocinski F, Wrobel G, Gack S, et al. Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing. Oncogene 2004; 23: 7005–7017. doi: 10.1038/sj.onc.1207938 15273721

7. Hübner G, Brauchle M, Smola H, Madlener M, Fässler R, Werner S. Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 1996; 8: 548–556. doi: 10.1006/cyto.1996.0074 8891436

8. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738–746. doi: 10.1056/NEJM199909023411006 10471461

9. Weinheimer-Haus EM, Mirza RE, Koh TJ. Nod-like receptor protein-3 inflammasome plays an important role during early stages of wound healing. PLoS One 2015; 10: e0119106. doi: 10.1371/journal.pone.0119106 25793779

10. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207–214. doi: 10.1038/nrm763 11994741

11. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617–629. doi: 10.1038/nri1418 15286728

12. Ravanti L, Kähäri VM. Matrix metalloproteinases in wound repair. Int J Mol Med 2000; 6: 391–407. 10998429

13. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 2006; 10: 143–155. doi: 10.1517/14728222.10.1.143 16441234

14. Chaudhary AK, Pandya S, Ghosh K, Nadkarni A. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res 2013; 753: 7–23. doi: 10.1016/j.mrrev.2013.01.002 23370482

15. Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int J Mol Sci 2016; 17: E868. doi: 10.3390/ijms17060868 27271600

16. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ. Matrix metalloproteinases. Br J Surg 1997; 84: 160–166. 9052425

17. Ågren MS, Schnabel R, Christensen LH, Mirastschijski U. Tumor necrosis factor-α-accelerated degradation of type I collagen in human skin is associated with elevated matrix metalloproteinase (MMP)-1 and MMP-3 ex vivo. Eur J Cell Biol 2015; 94: 12–21. doi: 10.1016/j.ejcb.2014.10.001 25457675

18. Babaei S, Bayat M. Pentoxifylline Accelerates Wound Healing Process by Modulating Gene Expression of MMP-1, MMP-3, and TIMP-1 in Normoglycemic Rats. J Invest Surg 2015; 28: 196–201. doi: 10.3109/08941939.2014.1002642 26087281

19. Li Y, Kilani RT, Rahmani-Neishaboor E, Jalili RB, Ghahary A. Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in vivo. J Invest Dermatol 2014; 134: 643–650. doi: 10.1038/jid.2013.303 23877570

20. Madlener M, Parks WC, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 1998; 242: 201–210. doi: 10.1006/excr.1998.4049 9665817

21. Tabandeh MR, Oryan A, Mohhammad-Alipour A, Tabatabaei-Naieni A. Silibinin regulates matrix metalloproteinase 3 (stromelysine1) gene expression, hexoseamines and collagen production during rat skin wound healing. Phytother Res 2013; 27: 1149–1153. doi: 10.1002/ptr.4839 22976003

22. Tabandeh MR, Oryan A, Mohammadalipour A. Polysaccharides of Aloe vera induce MMP-3 and TIMP-2 gene expression during the skin wound repair of rat. Int J Biol Macromol 2014; 65: 424–430. doi: 10.1016/j.ijbiomac.2014.01.055 24491493

23. Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 2007; 213: 355–364. doi: 10.1002/jcp.21208 17654499

24. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211: 19–26. doi: 10.1002/jcp.20948 17167774

25. Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 2010; 1803: 3–19. doi: 10.1016/j.bbamcr.2009.07.004 19631700

26. Yu T, Li YJ, Bian AH, Zuo HB, Zhu TW, Ji SX, et al. The regulatory role of activating transcription factor 2 in inflammation. Mediators Inflamm 2014; 2014: 950472. doi: 10.1155/2014/950472 25049453

27. Watson G, Ronai ZA, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res 2017; 119: 347–357. doi: 10.1016/j.phrs.2017.02.004 28212892

28. Westermarck J, Li S, Jaakkola P, Kallunki T, Grénman R, Kähäri VM. Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2. Cancer Res 2000; 60: 7156–7162. 11156425

29. Wilczynska KM, Gopalan SM, Bugno M, Kasza A, Konik BS, Bryan L, et al. A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J Biol Chem 2006; 281: 34955–34964. doi: 10.1074/jbc.M604616200 17012236

30. Song H, Ki SH, Kim SG, Moon A. Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res 2006; 66: 10487–10496. doi: 10.1158/0008-5472.CAN-06-1461 17079470

31. Hosseini M, Rose AY, Song K, Bohan C, Alexander JP, Kelley MJ, et al. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork. Invest Ophthalmol Vis Sci 2006; 47: 1469–1476. doi: 10.1167/iovs.05-0451 16565381

32. Hsieh HL, Lin CC, Shih RH, Hsiao LD, Yang CM. NADPH oxidase-mediated redox signal contributes to lipoteichoic acid-induced MMP-9 upregulation in brain astrocytes. J Neuroinflammation 2012; 9: 110. doi: 10.1186/1742-2094-9-110 22643046

33. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73–81. doi: 10.1172/JCI12466 11435459

34. Prontera C, Crescenzi G, Rotilio D. Inhibition by Interleukin-4 of stromelysin expression in human skin fibroblasts: role of PKC. Exp Cell Res 1996; 224: 183–188. doi: 10.1006/excr.1996.0126 8612684

35. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 567–572. doi: 10.1007/s004030050241 9373715

36. Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffetter-Kochanek K. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem 2000; 275: 4336–4344. doi: 10.1074/jbc.275.6.4336 10660603

37. Tsuchiya H, Nakano R, Konno T, Okabayashi K, Narita T, Sugiya H. Activation of MEK/ERK pathways through NF-κB activation is involved in interleukin-1β-induced cyclooxygenease-2 expression in canine dermal fibroblasts. Vet Immunol Immunopathol 2015; 168: 223–232. doi: 10.1016/j.vetimm.2015.10.003 26549149

38. Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analy Biochem 1976; 72: 248–254.

39. Baecker V. ImageJ macro tool sets for biological image analysis. Paper presented at the ImageJ User and Developer Conference, Luxembourg, Centre de Recherche Public Henri Tudor, 2012.

40. Wilczynska KM, Gopalan SM, Bugno M, Kasza A, Konik BS, Bryan L, et al. A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J Biol Chem 2006; 281: 34955–34964. doi: 10.1074/jbc.M604616200 17012236

41. Sylvester J, El Mabrouk M, Ahmad R, Chaudry A, Zafarullah M. Interleukin-1 induction of aggrecanase gene expression in human articular chondrocytes is mediated by mitogen-activated protein kinases. Cell Physiol Biochem 2012; 30: 563–574. doi: 10.1159/000341438 22832115

42. Chambers M, Kirkpatrick G, Evans M, Gorski G, Foster S, Borghaei RC. IL-4 inhibition of IL-1 induced Matrix metalloproteinase-3 (MMP-3) expression in human fibroblasts involves decreased AP-1 activation via negative crosstalk involving of Jun N-terminal kinase (JNK). Exp Cell Res 2013; 319: 1398–1408. doi: 10.1016/j.yexcr.2013.04.010 23608488

43. Sinfield JK, Das A, O'Regan DJ, Ball SG, Porter KE, Turner NA. p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem Biophys Res Commun 2013; 430: 419–424. doi: 10.1016/j.bbrc.2012.11.071 23206705

44. Wang Q, Siminovitch KA, Downey GP, McCulloch CA. Ras-guanine-nucleotide-releasing factors 1 and 2 interact with PLCγ at focal adhesions to enable IL-1-induced Ca2+ signalling, ERK activation and MMP-3 expression. Biochem J 2013; 449: 771–782. doi: 10.1042/BJ20121170 23145787

45. Gupta S, Campbell D, Dérijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389–393. doi: 10.1126/science.7824938 7824938

46. Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006; 208: 401–407. doi: 10.1002/path.1910 16369914

47. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1997; 1754: 253–262.

48. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689–737. doi: 10.1152/physrev.00028.2011 22535895

49. Martins VL, Caley M, O'Toole EA. Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res 2013; 351: 255–268. doi: 10.1007/s00441-012-1410-z 22526628

50. Utz ER, Elster EA, Tadaki DK, Gage F, Perdue PW, Forsberg JA, et al. Metalloproteinase expression is associated with traumatic wound failure. J Surg Res 2010; 159: 633–639. doi: 10.1016/j.jss.2009.08.021 20056248

51. Bullard KM, Lund L, Mudgett JS, Mellin TN, Hunt TK, Murphy B, et al. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg 1999; 230: 260–265. doi: 10.1097/00000658-199908000-00017 10450741

52. Bullard KM, Mudgett J, Scheuenstuhl H, Hunt TK, Banda MJ. Stromelysin-1-deficient fibroblasts display impaired contraction in vitro. J Surg Res 1999; 84: 31–34. doi: 10.1006/jsre.1999.5599 10334885

53. Li XY, Green MR. Intramolecular inhibition of activating transcription factor-2 function by its DNA-binding domain. Genes Dev 1996; 10: 517–527. doi: 10.1101/gad.10.5.517 8598283

54. Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL, et al. Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Mol Endocrinol 1992; 6: 2079–2089. doi: 10.1210/mend.6.12.1337144 1337144

55. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995; 14: 1798–1811. 7737130

56. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16: 459–467. doi: 10.1128/mcb.16.2.459 8552071

57. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 1991; 88: 3720–3724. doi: 10.1073/pnas.88.9.3720 1827203

58. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131–E136. doi: 10.1038/ncb0502-e131 11988758

59. Fuchs SY, Tappin I, Ronai Z. Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 2000; 275: 12560–12564. doi: 10.1074/jbc.275.17.12560 10777545

60. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270: 7420–7426. doi: 10.1074/jbc.270.13.7420 7535770

61. Zhu F, Zhang Y, Bode AM, Dong Z. Involvement of ERKs and mitogen- and stress-activated protein kinase in UVC-induced phosphorylation of ATF2 in JB6 cells. Carcinogenesis 2004; 25: 1847–1852. doi: 10.1093/carcin/bgh202 15192015

62. Ouwens DM, de Ruiter ND, van der Zon GC, Carter AP, Schouten J, van der Burgt C, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 2002; 21: 3782–3793. doi: 10.1093/emboj/cdf361 12110590

63. Gao D, Bing C. Macrophage-induced expression and release of matrix metalloproteinase 1 and 3 by human preadipocytes is mediated by IL-1β via activation of MAPK signaling. J Cell Physiol 2011; 226: 2869–2880. doi: 10.1002/jcp.22630 21935932

64. Sinfield JK, Das A, O'Regan DJ, Ball SG, Porter KE, Turner NA. p38 MAPK α mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem Biophys Res Commun 2013; 430: 419–424. doi: 10.1016/j.bbrc.2012.11.071 23206705

65. Hwang BM, Noh EM, Kim JS, Kim JM, You YO, Hwang JK, et al. Curcumin inhibits UVB-induced matrix metalloproteinase-1/3 expression by suppressing the MAPK-p38/JNK pathways in human dermal fibroblasts. Exp Dermatol 2013; 22: 371–374. doi: 10.1111/exd.12137 23614750

66. Kitanaka T, Nakano R, Kitanaka N, Kimura T, Okabayashi K, Narita T, et al. JNK activation is essential for activation of MEK/ERK signaling in IL-1β-induced COX-2 expression in synovial fibroblasts. Sci Rep 2017; 7: 39914. doi: 10.1038/srep39914 28054591

67. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663–675. doi: 10.1016/0092-8674(91)90098-j 2032290

68. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114–127. doi: 10.1016/j.molcel.2010.02.020 20385094

69. Meloche S. Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J Cell Physiol 1995; 163: 577–588. doi: 10.1002/jcp.1041630319 7775600

70. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–139. 9561267

71. Cobb MH, Goldsmith EJ. Dimerization in MAP-kinase signaling. Trends Biochem Sci 2000; 25: 7–9. doi: 10.1016/s0968-0004(99)01508-x 10637602

72. Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J, et al. ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology 2007; 45: 1035–1045. doi: 10.1002/hep.21551 17393467

73. Li F, Fan C, Cheng T, Jiang C, Zeng B. Efficient inhibition of fibroblast proliferation and collagen expression by ERK2 siRNAs. Biochem Biophys Res Commun 2009; 382: 259–263. doi: 10.1016/j.bbrc.2009.02.165 19285964

74. Shin J, Yang J, Lee JC, Baek KH. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. Cell Signal 2013; 25: 2540–2547. doi: 10.1016/j.cellsig.2013.08.014 23993963

75. Radtke S, Milanovic M, Rossé C, De Rycker M, Lachmann S, Hibbert A, et al. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci 2013; 126: 2381–2391. doi: 10.1242/jcs.115832 23549785

76. Namba S, Nakano R, Kitanaka T, Kitanaka N, Nakayama T, Sugiya H. ERK2 and JNK1 contribute to TNF-α-induced IL-8 expression in synovial fibroblasts. PLoS One 2017; 12: e0182923. doi: 10.1371/journal.pone.0182923 28806729

77. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657–672. doi: 10.1038/nrc884 12209155


Článek vyšel v časopise

PLOS One


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Výhody léčby pacientů s DM 2. typu GLP-1 agonisty
nový kurz
Autoři: prof. MUDr. Martin Haluzík, DrSc.

Syndrom suchého oka – diagnostika, komplikace a léčba
Autoři: MUDr. Petr Výborný, CSc., FEBO

Systémová léčba psoriázy
Autoři: MUDr. Jiří Horažďovský, Ph.D

Klinická farmakokinetika betablokátorů
Autoři:

Současné možnosti terapie osteoartrózy
Autoři: MUDr. Jakub Holešovský

Všechny kurzy
Kurzy Doporučená témata